Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/7/2018
SIETES contiene 92427 citas

 
 
 1 a 20 de 318 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Sánchez Caballero D. España mira para otro lado mientras cada vez más países regulan el uso del cannabis. eldiario.es 2018:30 de junio. [Ref.ID 102693]
2. Cita con resumen
Joseph A. FDA approves country’s first medicine made from marijuana. STAT Daily Recap 2018:2. [Ref.ID 102664]
3.Enlace a cita original Cita con resumen
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM, for the GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 2018;378:17 de mayo. [Ref.ID 102609]
4. Cita con resumen
Gorelick DA. The effects of cannabis among adults with chronic pain. Ann Intern Med 2018;168:525. [Ref.ID 102602]
5.
Anónimo. Australia becomes fourth nation to allow medicinal marijuana exports. DIA Daily 2018:4 de enero. [Ref.ID 102442]
6.
Whitlock J. Cannabis-derived drug granted priority review. San Diego Business Journal 2018:2 de enero. [Ref.ID 102441]
8. Cita con resumen
O'Neil ME, Nugent SM, Morasco BJ, Freeman M, Low A, Kondo K, Zakher B, Elven C, Motu'apuaka M, Paynter R, Kansagara D. Benefits and harms of plant-based cannabis for posttraumatic stress disorder: a systematic review. Ann Intern Med 2017;167:332-40. [Ref.ID 102023]
9. Cita con resumen
Nugent SM, Morasco BJ, O'Neil ME, Freeman M, Low A, Kondo K, Elven C, Zakher B, Motu'apuaka M, Paynter R, Kansagara D. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med 2017;167:319-31. [Ref.ID 102022]
10. Cita con resumen
Russo EB. Cannabidiol claims and misconceptions. Trends Pharmacol Sci 2017;38:198-201. [Ref.ID 101988]
11.Tiene citas relacionadas Cita con resumen
Berkovic SF. Cannabinoids for epilepsy — Real data, at last. N Engl J Med 2017;376:2075-6. [Ref.ID 101596]
12.Tiene citas relacionadas Cita con resumen
Devinsky O, Cross JH, Laux L, Marsh E, Nabbout R, Scheffer IE, Thiele EA, Wright S, for the Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376:2011-20. [Ref.ID 101595]
13.Tiene citas relacionadas Cita con resumen
Wong J, Motulski A, Abrahamowicz M, McGill J, Eguale T, Buckeridge DL, Tamblyn R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ 2017;356:j603. [Ref.ID 101417]
14.Tiene citas relacionadas Cita con resumen
Morales DR, Guthrie B. Off-label prescribing of antidepressants. BMJ 2017;356:j849. [Ref.ID 101416]
15. Cita con resumen
Anónimo. Brazil issues first license for sale of cannabis-based drug. DIA Daily 2017:1. [Ref.ID 101349]
17. Cita con resumen
Anónimo. Various states approve recreational, medical marijuana use. DIA Daily 2016:7. [Ref.ID 100907]
20. Cita con resumen
Anónimo. Administration to remove roadblock to marijuana research. DIA Daily 2016:1. [Ref.ID 100571]
Seleccionar todas
 
 1 a 20 de 318 siguiente >>